Of 259 patients with known KRAS mutation status, 109 (42%) had KRAS-mutant NSCLC, including 61%, 43%, and 26% in PD-L1 ≥50%, 1–49%, and <1% cohorts, respectively (Table 1). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.